SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

Gut Liver. 2020;14(4):521-528.

Higher Tumor Cellularity in Resected Pancreatic Ductal Adenocarcinoma Is a Negative Prognostic Indicator.

, , , , , , ,

제1저자 조인국, 김혜령 · 교신저자 황진혁

소속 (4)
  1. Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  2. Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
  3. Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  4. Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

Abstract

BACKGROUND/AIMS Desmoplasia is a prominent feature of pancreatic ductal adenocarcinoma (PDA). Stromal desmoplasia reflects the low cellularity that is characteristic of PDA, and it may play a role in PDA chemoresistance. In this retrospective study, we evaluated the relationship between tumor cellularity in resected PDA specimens and long-term patient outcomes.

METHODS We retrospectively reviewed the data from 175 patients who underwent PDA resection between January 2010 and December 2015 at Seoul National University Bundang Hospital, and analyzed their clinicopathological features and the relationship between tumor cellularity (high vs low based on a cutoff of 30% cellularity) and patient outcomes.

RESULTS The high-cellularity group had significantly shorter overall survival (OS) (18.7 months vs 26.6 months, p=0.006) and disease-free survival (11.0 months vs 16.9 months, p=0.031) than the low-cellularity group. Multivariate analysis revealed that high tumor cellularity was an independent risk factor for poor OS (hazard ratio, 2.008; 95% confidence interval, 1.361 to 2.962; p<0.001). Adjuvant therapy improved OS in the low-cellularity group (16.3 months vs 41.3 months, p=0.001) but not in the high-cellularity group (15.9 months vs 24.4 months, p=0.107).

CONCLUSIONS Tumor cellularity in PDA specimens may be a prognostic and predictive biomarker that could aid in identifying patients who would benefit from adjuvant therapy for PDA.

Keywords

BiomarkerCarcinomaChemotherapyPrognosisTumor cellularityadjuvantpancreatic ductal

Figures

Fig. 1
Fig. 1 Flowchart illustrating inclusion/exclusion criteria of the study. SNUBH, Seoul National University Bundang Hospital; PDA, pancreatic ductal adenocarcinoma.
Fig. 2
Fig. 2 Kaplan-Meier estimates for (A) overall survival (HR, 1.674; 95% CI, 1.159–2.418; p=0.006) and (B) disease-free survival (HR, 1.536; 95% CI, 1.039–2.270; p=0.031) for patients stratified by tumor cellularity in of pancreatic ductal adenocarcinoma. HR, hazard ratio; CI, confidence interval.
Fig. 3
Fig. 3 Kaplan-Meier estimates of overall survival by the receipt of adjuvant therapy in the (A) low-cellularity group (HR, 0.380; 95% CI, 0.218–0.659; p=0.001) and (B) high-cellularity group (HR, 0.616; 95% CI, 0.342–1.110; p=0.107). HR, hazard ratio; CI, confidence interval.

그림 출처: PubMed Central 공개 논문 (PMC7366152)

그 밖의 정보
출판 형태
Journal Article
저널
Gut and liver · eISSN 2005-1212
MeSH
Aged · Carcinoma, Pancreatic Ductal* · Female · Humans · Male · Middle Aged · Pancreatic Neoplasms* · Prognosis · Retrospective Studies · Seoul
참고문헌
31편